Welcome to our dedicated page for Ocular Therapeutix news (Ticker: OCUL), a resource for investors and traders seeking the latest updates and insights on Ocular Therapeutix stock.
Ocular Therapeutix, Inc. reports news around ophthalmic drug development, commercial product activity and corporate governance for a Nasdaq-listed biopharmaceutical company using ELUTYX proprietary bioresorbable hydrogel formulation technology. Recurring updates focus on AXPAXLI, also known as OTX-TKI, an axitinib intravitreal hydrogel candidate for retinal disease, including wet age-related macular degeneration and diabetic retinal disease such as non-proliferative diabetic retinopathy.
Company announcements also cover DEXTENZA, an FDA-approved corticosteroid for ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, as well as OTX-TIC, a travoprost intracameral hydrogel program for open-angle glaucoma or ocular hypertension. Other recurring items include financial results, scientific and investor conference participation, clinical-study presentations and inducement equity grants under Nasdaq Listing Rule 5635(c)(4).
Ocular Therapeutix (OCUL) granted inducement equity awards to nine newly hired non-executive employees effective September 14, 2026, under its 2019 Inducement Stock Incentive Plan and Nasdaq Listing Rule 5635(c)(4).
The awards comprise non-statutory stock options for up to an aggregate of 64,850 shares and restricted stock units (RSUs) for an aggregate of 21,350 shares of common stock. The stock options have a ten-year term and an exercise price of $10.72 per share, equal to the Nasdaq Global Market closing price on the grant date. Options vest over four years, with 25% after one year and the remainder in equal monthly installments over the next three years, subject to continued service. RSUs vest in three equal annual installments over three years, also subject to continued service and the terms of the award agreements and plan.
Ocular Therapeutix (OCUL) completed a positive Pre-New Drug Application (Pre-NDA) meeting with the U.S. FDA for AXPAXLI™ (OTX-TKI) in wet age-related macular degeneration and remains on track to submit an NDA in the fourth quarter of 2026.
The FDA indicated alignment with an NDA package based on Week 52 efficacy and safety data from the registrational Phase 3 SOL-1 trial, interim safety data from the ongoing Phase 3 SOL-R trial, and supporting confirmatory evidence, including subjects who have received multiple AXPAXLI injections to support repeat dosing. SOL-1, conducted under a Special Protocol Assessment, met its pre-specified primary endpoint with high statistical significance in February 2026. The planned submission will use the 505(b)(2) pathway, which the company states may shorten the FDA review timeline by up to 60 days compared with the 505(b)(1) pathway, and commercial preparations are advancing ahead of a potential 2027 launch.
Ocular Therapeutix (NASDAQ: OCUL) will participate in multiple investor and scientific conferences in September and October 2026, including Wells Fargo and Baird healthcare investor events with a webcasted fireside chat, and several retina-focused meetings where Phase 3 SOL-1 trial results for OTX-TKI in neovascular AMD will be presented.
Ocular Therapeutix (NASDAQ: OCUL) granted equity inducement awards to its new SVP, Government Affairs and Public Policy, Beth Rada, under its 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The awards, effective August 10, 2026, include a non-statutory option to purchase up to 85,000 shares at an exercise price of $9.24 per share, with a ten-year term and four-year vesting schedule, and restricted stock units covering 28,000 shares vesting in three equal annual installments, all subject to continued service and applicable award agreement terms.
Ocular Therapeutix (NASDAQ: OCUL) granted inducement equity awards to eight newly hired non-executive employees under its 2019 Inducement Stock Incentive Plan, effective August 3, 2026, in line with Nasdaq Listing Rule 5635(c)(4).
The grants cover non-statutory stock options for up to 53,975 shares at an exercise price of $8.40 per share with a ten-year term, plus restricted stock units for 17,450 shares. Options vest over four years (25% after one year, then monthly for three years) and RSUs vest in three equal annual installments, all subject to continued service.
Ocular Therapeutix (NASDAQ: OCUL) reported second quarter 2026 results and detailed progress on its AXPAXLI (OTX-TKI) retina franchise. According to Ocular Therapeutix, an NDA for AXPAXLI in wet AMD is planned for Q4 2026 under the Section 505(b)(2) pathway, following a positive FDA Type C meeting and a pre-NDA meeting scheduled for Q3 2026. The filing will rely on SOL-1 Week 52 efficacy and safety data plus interim SOL-R safety data, targeting an aggregate safety set of over 300 patients with at least one year of exposure.
A post-hoc SOL-1 analysis suggested up to an estimated 72% reduction in treatment burden versus projected on-label aflibercept (2 mg) over 60 weeks. Cash and equivalents were $598.6 million at June 30, 2026, with projected runway into 2028. Q2 2026 net revenue was $13.5 million, flat year over year, and net loss was $(78.8) million, or $(0.35) per share, as R&D, selling and marketing, and G&A expenses all increased to support Phase 3 trials and commercial readiness for a potential 2027 launch, if approved.
Ocular Therapeutix (NASDAQ: OCUL) granted inducement equity awards to eleven newly hired non-executive employees under its 2019 Inducement Stock Incentive Plan, consistent with Nasdaq Listing Rule 5635(c)(4).
Awards, effective July 6, 2026, include options for 34,700 shares at $9.66 and 11,375 RSUs with multi‑year vesting schedules.
Ocular Therapeutix (NASDAQ: OCUL) plans several July 2026 scientific and investor appearances. The company will present at the OIS Retina Innovation Summit on July 14 in Montréal and at the ASRS 44th Annual Meeting July 15–18, highlighting OTX-TKI Phase 3 SOL-1 results and nAMD data.
Ocular will also join the HC Wainwright 6th Annual Ophthalmology Virtual Conference on July 22 with a webcast fireside chat for investors.
Ocular Therapeutix (NASDAQ: OCUL) granted inducement equity awards to new SVP, Market Access and Health Policy, Kelley Allison, under its 2019 Inducement Stock Incentive Plan in line with Nasdaq Rule 5635(c)(4).
Awards include options for 85,000 shares at $8.99 and 28,000 RSUs with multi‑year vesting.
Ocular Therapeutix (NASDAQ: OCUL) plans to submit a U.S. FDA‑aligned NDA for AXPAXLI™ in wet AMD in 4Q 2026. The filing will rely on SOL‑1 Week 52 efficacy and safety plus interim SOL‑R safety to exceed 300 treated patients, using the 505(b)(2) pathway.
SOL‑R efficacy data will not be in the NDA; the trial will remain masked to Week 96 to assess new secondary endpoints versus aflibercept, with topline results expected in 1Q 2028. The company will also prioritize a single global Phase 3 DR trial, HELIOS‑3, evaluating once‑yearly AXPAXLI.